Eli Lilly to invest $3.5 billion in building a new factory in the US to produce next-generation obesity drugs

Glonghui, January 31｜Eli Lilly announced that it will invest over $3.5 billion to build a manufacturing plant in Lehigh Valley, Pennsylvania, marking the fourth facility in a series of new investment projects in the United States. This plant will help produce the company's next-generation obesity drugs. The company stated that this includes the experimental drug retatrutide, which has shown the highest weight loss efficacy among all treatments to date in late-stage trials. The company expects construction of the Pennsylvania plant to begin this year and to commence operations in 2031.